Peak Financial Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-4,835
Closed -$248K 68
2022
Q4
$248K Buy
+4,835
New +$232K 0.23% 51
2022
Q3
Sell
-3,996
Closed -$210K 67
2022
Q2
$210K Sell
3,996
-10,736
-73% -$547K 0.21% 64
2022
Q1
$763K Sell
14,732
-299
-2% -$15.5K 0.65% 40
2021
Q4
$888K Buy
15,031
+3,813
+34% +$189K 0.68% 33
2021
Q3
$482K Buy
+11,218
New +$497K 0.42% 39

Other funds holding PFE

Peak Financial Advisors's PFE Position: Q1 2023 in Review

Peak Financial Advisors sold out of Pfizer (PFE) in Q1 2023, closing a stake of 4,835 shares — an estimated $248K sold.

Peak Financial Advisors first reported a position in PFE in Q3 2021 and held it in 5 quarters. The position peaked at $888K in Q4 2021. 3,102 funds tracked by Wall St. Rank hold PFE as of Q1 2023.

  • Peak Financial Advisors reported no remaining Pfizer position as of Q1 2023 after selling out during the quarter.
  • Peak Financial Advisors sold 4,835 Pfizer shares in Q1 2023, an estimated $248K.
  • Peak Financial Advisors first reported a position in Pfizer in Q3 2021 and held it in 5 quarters.
  • Peak Financial Advisors's Pfizer position peaked at $888K in Q4 2021.
  • 3,102 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.

Based on Peak Financial Advisors's 13F filing for Q1 2023, filed 19 Apr 2023.